News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
898.6 ^USD	-0.68%		-4.25%	+2.31%

01:42pm	Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	MT
Apr. 11	Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	07:42am	MT
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
News Highlights : Top Company News of the Day - Thursday at 5 AM ET	Apr. 11	DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET	Apr. 11	DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Apr. 11	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET	Apr. 10	DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET	Apr. 10	DJ
US DOJ Files Complaint Against Regeneron Pharmaceuticals for Alleged Fraudulent Drug Price Reporting	Apr. 10	MT
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET	Apr. 10	DJ
US DOJ Files Complaint Against Regeneron Pharmaceuticals for Alleged Fraudulent Drug Price Reporting	Apr. 10	MT
US Justice department files complaint against Regeneron, alleges fraudulent drug pricing	Apr. 10	RE
US accuses Regeneron of fraudulent price reporting for eye drug	Apr. 10	RE
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen	Apr. 09	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating	Apr. 09	MT
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma	Apr. 07	AQ
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma	Apr. 07	GL
Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma	Apr. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Summary

Filters